USPTO serial 79418680
TASLY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 27, 2026
- Examiner
- SUK, HAE P
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with TASLY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd.
CN
Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Zhi Dong
Zhi Dong HSML, P. C.45 South Seventh Street, Suite 2700Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicine for human purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; chemico-pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; biomedicine for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; herbs for medicinal purposes; medicines made of Chinese traditional medicinal herbs for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; capsules for medicines, namely, capsules sold empty for pharmaceuticals; pharmaceutical preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; dietetic food and beverages adapted for medical use; bath preparations, medicated; medical analgesic preparations; preparations for the treatment of burns; syrups for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; vitamin preparations; sunburn preparations for pharmaceutical purposes; vaccines; detergents for medical purposes; disinfectants for hygiene purposes; digestives for pharmaceutical purposes; mineral water for medical purposes; mineral salts for medical purposes; purgatives; meal for pharmaceutical purposes; flour for pharmaceutical purposes; febrifuges; medicinal tea; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; anthelmintics; pharmaceutical gelatin, namely, gelatin capsules sold empty for pharmaceuticals; germicides; greases for medical purposes; chemical preparations for the diagnosis of pregnancy; medicinal oils, other than essential oils; medicinal herbs; lotions for pharmaceutical purposes, namely, anti-bacterial hand wash, medicated oral rinse, gynecological vaginal wash for medical purposes, anorectal wash for medical purposes; ointments for pharmaceutical purposes, namely, sunburn ointments, anti-inflammatory ointments, hemorrhoidal ointments, frostbite salve for pharmaceutical purposes, eye ointments for medical use; pectin for pharmaceutical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; herbs teas for medicinal purposes; pharmaceutical preparations for skin care; pharmaceutical preparations for treating dandruff; first-aid boxes, filled; medicinal roots; medicinal herbal preparations, namely, medicated tonics for treating cardiovascular disease, AMS, heart failure, cardiovascular and cerebrovascular disease; sedatives; soporifics; sugar for medical purposes; biological preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medical preparations for slimming purposes; by-products of the processing of cereals for dietetic or medical purposes; medicines for dental purposes; diagnostic preparations for medical purposes for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medicinal drinks; ferments for pharmaceutical purposes; chemical reagents for medical or veterinary purposes; dietary fiber to aid digestion; enzyme preparations for medical purposes; amino acids for pharmaceutical purposes; mouthwashes for medical purposes; appetite suppressants for medical purposes; adjuvants for medical purposes; weight-reducing aid, namely, weight management supplements; pharmaceutical preparations for the treatment of sunburns; food supplements, namely, antioxidants used for medicinal purposes; acne treatment preparation; medicinal herbal preparations, namely, lysine electuary for medicinal use; oral rehydration salts; medicinal liquor, namely, medicinal alcohol for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medicinal herbal preparations, namely, ginseng electuary for medicinal use; ginseng for medicinal use; medicinal herbal preparations, namely, medlar; dietetic beverages adapted for medicinal purposes, namely, weight-reducing tea; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; nutritional food additives for medical purposes in the nature of natural food extracts derived from fish, meat, vegetables, fruits; food for babies; milk powder for infants; air purifying preparations; medicated animal washes; veterinary preparations for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS), diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis; medicated animal feed; biocides; vermin destroying preparations; sanitary towels; wadding for medical purposes; medical dressings; rubber for dental purposes; teeth filling material; diaper for pets; raw material medicine, namely, pill, tablet, capsule, liquid drops, granule for the secondary prevention of coronary heart disease (CHD) and the treatment of acute maintain sickness (AMS) , diabetic retinopathy, asthma, cancer, cardiovascular and cerebrovascular disease, coronary artery disease, angina pectoris, myocardial infarction, cough, depression, diabetes and its complications, enteritis, febris, headache, heart disease, hepatitis, hepatopathy, high blood pressure, hypertriglyceridemia, hypercholesteremia, combined hyperlipidemia, insomnia, fatty liver disease, respiratory tract infection, psychosis, rhinitis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks owned by Tasly Pharmaceutical Group Co., Ltd.
- Other trademarks in Class 005
- Similar marks named TASLY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 20, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 5, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 5, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 5, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 5, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 27, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 27, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 27, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 11, 2025 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 9, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 9, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 3, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 26, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 25, 2025 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 11, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 11, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 11, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 11, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 11, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 28, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 28, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 28, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 28, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 9, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 9, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 6, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 21, 2025 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Mar 6, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |